H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on BNTX stock, giving a Buy rating on September 9. Robert Burns has ...

MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the ...

the investigational CAR-T cell therapy BNT211, and the investigational ADC therapy BNT323/DB-1303; the nature and characterization of and timing for release of clinical data across BioNTech’s ...

(Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European ...

the investigational CAR-T cell therapy BNT211, and the investigational ADC therapy BNT323/DB-1303; the nature and characterization of and timing for release of clinical data across BioNTech’s ...

(MENAFN- GlobeNewsWire - Nasdaq) MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX,“BioNTech” or“the Company”) will present clinical trial data for selected assets from its ...

(Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology (“ESMO”) ...

BNT211 combines autologous CAR-T cells directed ... is consistent with the previously published data of CAR-T therapies. BioNTech has established a diversified clinical oncology pipeline including ...

BioNTech is shifting its focus towards its oncology pipeline, with several key updates expected in the near future. These updates include Phase 1/2 data for BNT113 in HPV16-induced carcinomas, BNT327 ...